EVOGENE LTD (EVGN) Stock Price, Quote, News and Overview
NASDAQ:EVGN - Nasdaq - IL0011050551 - Common Stock - Currency: USD
EVGN Quote, Performance and Key Statistics
EVOGENE LTD
NASDAQ:EVGN (1/29/2025, 8:21:43 PM)
After market: 1.57 0 (0%)1.57
+0.03 (+1.95%)
The current stock price of EVGN is 1.57 USD. In the past month the price decreased by -4.85%. In the past year, price decreased by -79.57%.
EVGN Latest News, Press Releases and Analysis
Evogene Reports Third Quarter 2024 Financial Results
Conference call and webcast: today, November 21, 2024, 9:00 am ET Financial Highlights: In the first nine months of 2024, total revenues reached approximately...
Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results
/PRNewswire/ -- Lavie Bio Ltd., a leading ag-biologicals company and subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), today announced significant...
Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials
/PRNewswire/ -- Lavie Bio Ltd., a leading ag-biologicals company and a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), today announced the commercial...
Evogene Schedules Third Quarter 2024 Financial Results Release
/PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and...
EVGN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.3 | 309.71B | ||
| AMGN | AMGEN INC | 14.66 | 151.41B | ||
| GILD | GILEAD SCIENCES INC | 21.58 | 119.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 865.73 | 113.70B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.13 | 75.52B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.15B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.34B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.20B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.14B | ||
| NTRA | NATERA INC | N/A | 22.21B | ||
| BIIB | BIOGEN INC | 8.84 | 21.04B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.37 | 16.64B |
Related stock screener links
About EVGN
Company Profile
Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
Company Info
EVOGENE LTD
13 Gad Feinstein Street, Park Rehovot
Rehovot 7414002 IL
CEO: Ofer Haviv
Employees: 142
Company Website: https://evogene.com/
Investor Relations: http://investors.evogene.com/
Phone: 97289311900
EVGN FAQ
What is the stock price of EVGN?
The current stock price of EVGN is 1.57 USD.
What is the symbol for EVOGENE LTD stock?
The exchange symbol of EVOGENE LTD is EVGN and it is listed on the Nasdaq exchange.
On which exchange is EVGN stock listed?
EVGN stock is listed on the Nasdaq exchange.
Is EVGN a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for EVGN, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of EVGN.
Does EVGN stock pay dividends?
EVGN does not pay a dividend.
What is the Price/Earnings (PE) ratio of EVGN?
EVGN does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.47).
What is the Short Interest ratio of EVGN stock?
The outstanding short interest for EVGN is 0.4% of its float.
EVGN Technical Analysis
EVGN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to EVGN. EVGN may be in some trouble as it scores bad on both profitability and health.
EVGN Financial Highlights
Over the last trailing twelve months EVGN reported a non-GAAP Earnings per Share(EPS) of -4.47. The EPS decreased by 4.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -58.62% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
EVGN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to EVGN. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 20.81% and a revenue growth 89.65% for EVGN